Bio-Techne Corporation TECH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +23.55%
- 1 year
- +19.19%
- Open
- 72.72
- Prev close
- 72.71
- Mkt cap
- 11.41B
- Vol
- 2.57M
- Avg vol
- 2.84M
- EPS
- 1.16
- P/E
- 62.64
- Div yield
- 0.44%
More statistics
- Low
- 72.66
- High
- 72.73
- Forward P/E
- 31.44
- Beta
- 1.29
- Short ratio
- 2.42
- Inst. own
- 112.55%
- Dividend
- 0.32
- Ex-div date
- Aug 23, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 72.44
- 200-d avg
- 63.13
- 1y target
- 70.50
30m chart
Built from the cached five-day intraday bars.
Signals (12)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 1:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:55 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:55 PM | 1 day ago |
| MACD: Buy Signal | Oct 28, 4:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 4 days ago |
Key statistics
- Market cap
- 11.41B
- Enterprise value
- 11.43B
- Trailing P/E
- 62.64
- Forward P/E
- 31.44
- PEG ratio
- 2.17
- Price / sales
- 9.39
- Price / book
- 5.38
- EPS (TTM)
- 1.16
- Beta
- 1.29
- Dividend yield
- 0.44%
- Payout ratio
- 27.59%
- Profit margin
- 14.97%
- Revenue (TTM)
- 1.22B
- Revenue growth
- 1.30%
- Free cash flow
- 229.65M
- Total cash
- 265.48M
- Total debt
- 289.09M
- Return on equity
- 9.03%
- Shares outstanding
- 157.06M
- Short % of float
- 4.82%
- 50-day average
- 72.44
- 200-day average
- 63.13
Analyst view
Consensus: hold
- Target (low)
- 50.00
- Target (mean)
- 70.50
- Target (high)
- 73.00
- Strong buy0
- Buy0
- Hold12
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.44764.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.44 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | 0.519 | 0.52 | 0.00 | +0.19% |
| May 6, 2026 | Mar 31, 2026 | 0.55 | 0.53 | -0.02 | -3.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 30, 2025 | 0.4214 | 0.42 | 0.00 | -0.33% |
| Aug 6, 2025 | Jun 30, 2025 | 0.50 | 0.53 | +0.03 | +6.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 9, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Jun 30, 2026 | TD Cowen | down | Buy | Hold |
| Jun 30, 2026 | Benchmark | down | Buy | Hold |
| Jun 29, 2026 | Citigroup | down | Buy | Neutral |
| Jun 26, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bio-techne.com
News
- Conestoga SMid Cap Composite Q3 2026 Portfolio Activity
- Press release: CMB.TECH fleet update
- CMB.TECH SPECIAL GENERAL MEETING RESULTS
- Bio-Techne Opens New Bristol Facility
- Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
- INCY or TECH: Which Is the Better Value Stock Right Now?
- INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
- Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?
- Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
- Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Your note
Sign in to keep a note on TECH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director | Stock Award(Grant) | Oct 29, 2025 | 46,503 |
| BOHNEN SHANE | General Counsel | Conversion of Exercise of derivative security | Aug 13, 2026 | 10,360 |
| GEIST WILLIAM | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 24,943 |
| HIGGINS JOHN L | Director | Conversion of Exercise of derivative security | Sep 27, 2026 | 77,254 |
| HIPPEL JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 170,183 |
| KEEGAN JOSEPH D | Director | Stock Award(Grant) | Oct 29, 2025 | 15,411 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 14,025,816 | 1.02B | Jun 29, 2026 |
| FMR, LLC | 8.15% | 12,794,784 | 929.73M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.51% | 10,218,558 | 742.53M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.68% | 7,343,324 | 533.60M | Jun 29, 2026 |
| HBK Investments L P | 4.35% | 6,825,000 | 495.94M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.14% | 6,506,360 | 472.78M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 4,968,867 | 361.06M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.58% | 4,056,808 | 294.79M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,586,562 | 260.62M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.72% | 2,707,457 | 196.74M | Sep 29, 2026 |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 1.66% | 2,604,519 | 189.26M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,089,474 | 151.83M | Sep 29, 2026 |